Zeng, Zhiming
Liao, Xiwen
Huang, Ketuan
Han, Chuangye
Qin, Wei
Su, Hao
Ye, Xinping
Yang, Chengkun
Zhou, Xin
Wei, Yongguang
Mo, Shutian
Liu, Junqi
Lan, Chenlu
Huang, Xinlei
Huang, Zaida
Peng, Kai
Gao, Qiang
Peng, Tao
Zhu, Guangzhi
Funding for this research was provided by:
2023 Huai Er Special Fund for Cancer Prevention and Treatment Research of Chen Xiao-Ping Foundation of The Development of Science and Technology of Hubei Province (CXPJJH123003-018)
Chinese foundation for hepatitis prevention and control—TianQing liver disease research fund subject (TQGB20210077)
the Self‑raised Scientific Research Fund of the Health and Family Planning Commission of the Guangxi Zhuang Autonomous Region (Z-A20230458)
Key Laboratory of early Prevention & Treatment for regional High Frequency Tumor (Guangxi Medical University)-Ministry of Education (GKE-ZZ202213, GKE-ZZ202109 and GKE-ZZ202009)
Innovation Project of Guangxi Graduate Education (YCSW2022227)
2022 Huai Er Special Fund for Cancer Prevention and Treatment Research of Chen Xiao-Ping Foundation of The Development of Science and Technology of Hubei Province (CXPJJH122002-080)
National Nature Science Foundation of China (82360465)
Article History
Received: 28 April 2023
Accepted: 3 October 2023
First Online: 13 October 2023
Declarations
:
: This study protocol was reviewed and approved by the Ethics Committee of The First Affiliated Hospital of Guangxi Medical University, approval number NO.2022-KY-E-(218).
: Not applicable.
: The authors declare no competing interests.